Key Highlights
- EVE Health Group (ASX:EVE) signed a binding Australian compounding and profit-share agreement for its men’s health range.
- The pharmacy partner will source ingredients, compound and dispense products and arrange delivery.
- EVE is entitled to 75% of the profit available for distribution after specified direct costs.
- First Supply depends on readiness steps including technology transfer and validation.
EVE Health Group (ASX:EVE) develops pharmaceutical products and formulation technology. On 10 November 2026, it announced an Australian agreement for a pharmacy partner to compound and dispense products from its men’s health range. The agreement sets out the responsibilities of each party, conditions for first supply and the basis for sharing proceeds.
Pharmacy and company responsibilities
EVE will provide formulation technology, technical knowledge and commercial support. The pharmacy partner is responsible for sourcing ingredients, compounding, dispensing and arranging delivery. EVE said it plans to engage telehealth partners, with prescribing decisions remaining with independent clinicians. The filing described the products as intended to be prepared for individual patients against valid prescriptions. First supply is subject to conditions including completion of technology transfer and validation. The pharmacy’s appointment for the initial products is exclusive in Australia from first supply under the terms disclosed.
The range uses EVE’s patent-pending nano-emulsion technology. It names erectile dysfunction and premature ejaculation as intended uses under development. The announcement says compounded medicines are prepared by a pharmacist for an individual patient. The Therapeutic Goods Administration’s guidance states that it does not evaluate compounded medicines for safety, quality or efficacy.
Profit split and eligible direct costs
EVE is entitled to 75% of the profit available for distribution and the pharmacy partner receives 25%. The agreement defines the amount as net patient revenue, excluding GST, refunds and chargebacks, less direct compounding and delivery costs. Those costs include ingredients, packaging, delivery and a fixed labour amount per unit. The company said the agreement does not provide for a Margin or markup on those items and that rebates and savings are passed through. EVE will pay telehealth support fees from its share. The agreement requires no upfront payments or fixed fees from EVE.
Initial term and termination provisions
The initial term runs for two years from first supply. It renews automatically for successive 12-month periods unless a party gives 90 days’ notice before the end of the term. The disclosed terms also provide for termination on 30 days’ notice for an unresolved material breach or immediate termination on Insolvency or loss of a necessary licence or approval. EVE may terminate if first supply does not occur within three months of signing, except where the delay is due to its own default.
Intellectual property and a separate product program
EVE retains ownership of the patent-pending formulation technology and related intellectual property, including improvements made under the agreement. The company said the agreement is separate from its Libbo vardenafil oral soluble film program, which was continuing separately along its already planned bioequivalence and registration pathway. The company disclosed no minimum volumes or guaranteed revenue. It said future Revenue would depend on when supply starts, prescribing decisions, patient demand, pricing and costs.
The agreement also sets terms for quality, safety reporting and confidentiality. It allows either party to terminate if a change in law or regulatory direction makes the arrangement unlawful and they cannot agree changes within 30 days. EVE said it would assess whether the model could support further products, subject to commercial and regulatory requirements.
The announcement establishes the commercial terms and the responsibilities for a proposed pharmacy-led supply arrangement. EVE’s stated next steps are completing the readiness work with its pharmacy partner and engaging telehealth providers before first supply.






Please wait processing your request...